Skip to main content
user-generated· price

Novo Nordisk stock rises 10% within 3 months of Wegovy pill launch

Novo Nordisk's stock will appreciate by at least 10% from the date of the Wegovy pill's private launch, reflecting investor optimism about the oral formulation's market penetration potential and its impact on revenue growth. The increase will be attributed to analyst upgrades and sales forecasts.

price · Prediction Market

Implied probability (Yes)
60%
Closes
2026-10-06

More price markets

Browse all price markets →

Loading…